Hbv mutations associated with reduced susceptibility to adefovir
CA 2500673 A1 · Owner: Xiong, Xiaofeng · Inventors: Delaney, William E.; Xiong, Xiaofeng
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Applicants have identified 5 mutants associated with hepatitis B virus resistance to adefovir, a nucleotide analogue antiviral drug widely employed in the therapy of hepatitis B. In accord with this invention reverse , transcriptase mutants rtN236T rtA181V, rtA181T and their corresponding surface antigen mutants sL173F and sL172trunc are provided. The mutant proteins, antibodies thereto and nucleic acids encoding the mutants have diagnostic value in monitoring and adjusting patient therapy with adefovir and in the therapy of patients infected with the mutants.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 1, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.